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Transdifferentiation of Blood-Derived Human Adult Endothelial
Progenitor Cells Into Functionally Active Cardiomyocytes
Cornel Badorff, MD; Ralf P. Brandes, MD; Rüdiger Popp, PhD; Stefan Rupp, MD;
Carmen Urbich, PhD; Alexandra Aicher, MD; Ingrid Fleming, MD; Rudi Busse, PhD;
Andreas M. Zeiher, MD; Stefanie Dimmeler, PhD
Background—Further to promoting angiogenesis, cell therapy may be an approach for cardiac regeneration. Recent studies
suggest that progenitor cells can transdifferentiate into other lineages. However, the transdifferentiation potential of
endothelial progenitor cells (EPCs) is unknown.
Methods and Results—EPCs were obtained from peripheral blood mononuclear cells of healthy adults or coronary artery
disease (CAD) patients by cultivating with endothelial cell medium and growth factors. After 3 days, .95% of adherent cells
were functionally and phenotypically EPCs. Diacetylated LDL–labeled EPCs were then cocultivated with rat cardiomyocytes
for 6 days, resulting in significant increases of EPC cell length and size to a cardiomyocyte-like morphology. Biochemically,
9.9461.39% and 5.0461.09% of EPCs from healthy adults (n515) or CAD patients (n514, P,0.01 versus healthy adults),
respectively, expressed a-sarcomeric actinin as measured by flow cytometry. Immunocytochemistry showed that human
EPCs expressed a-sarcomeric actinin, cardiac troponin I (both with partial sarcomeric organization), atrial natriuretic peptide,
and myocyte enhancer factor 2. Fluo 4 imaging demonstrated calcium transients synchronized with adjacent rat cardiomyo-
cytes in transdifferentiated human EPCs. Single-cell microinjection of Lucifer yellow and calcein-AM labeling of
cardiomyocytes demonstrated gap junctional communication between 5167% of EPCs (16 hours after labeling, n54) and
cardiomyocytes. EPC transdifferentiation into cardiomyocytes was not observed with conditioned medium but in coculture
with paraformaldehyde-fixed cardiomyocytes.
Conclusions—EPCs from healthy volunteers and CAD patients can transdifferentiate in vitro into functionally active
cardiomyocytes when cocultivated with rat cardiomyocytes. Cell-to-cell contact but not cellular fusion mediates EPC
transdifferentiation. The therapeutic use of autologous EPCs may aid cardiomyocyte regeneration in patients with
ischemic heart disease. (Circulation. 2003;107:1024-1032.)
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Anumber of cardiovascular diseases, such as myocar-dial infarction, lead to cardiomyocyte loss and con-
sequently deterioration of cardiac function. Because car-
diomyocytes have a severely limited capacity to divide and
thus replace damaged tissue, the use of a cardiovascular
cell therapy is a promising option to regenerate cardiac
tissue. Furthermore, the transplantation of healthy stem
cells may correct cellular dysfunction due to mutated
genes.1 Different types of stem or progenitor cells have
been shown to improve cardiac function in animal models
of myocardial infarction. Human hematopoietic CD341
progenitor cells or murine c-kit1/sca-11 bone marrow cells
have been used with similar beneficial effects.2,3 In addi-
tion, endothelial progenitor cells (EPCs) injected system-
ically have been reported to increase the neovasculariza-
tion of ischemic tissue.4 – 6
Bone marrow–derived EPCs in the peripheral blood were
first described by Asahara et al7 in 1997. These cells can be
expanded ex vivo from mononuclear cells4,6,8,9 or obtained by
culturing CD341 or CD1331 hematopoietic progenitor
cells.7,10–12 The differentiation of EPCs out of mononuclear
cells or hematopoietic progenitor cells was promoted by the
addition of endothelial growth factors, such as vascular
endothelial growth factor.7,11 EPCs are characterized by their
expression of the vascular endothelial growth factor receptor
2 (KDR), a marker for the angioblast lineage, and further
endothelial marker proteins (such as von Willebrand factor,
vascular endothelial cadherin, and endothelial nitric oxide
synthase), uptake of diacetylated LDL (Dil-acLDL), and
lectin binding.7,11,13,14 Blood-derived angioblasts or EPCs
expanded ex vivo have been reported to integrate into blood
vessels and improve neovascularization of ischemic hind
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limbs and hearts in animals.4,6,8,15 The improvement of
cardiac function by EPC transplantation was attributed to
their angiogenic potential. So far, the capacity of adult EPCs
to transdifferentiate into cardiomyocytes is unknown.
A recent study demonstrated that murine embryonic endo-
thelial cells can transdifferentiate into cardiac myocytes in
vitro and in vivo.16 Likewise, mouse and human embryonic
stem cells or human mesenchymal stromal cells can differ-
entiate into cardiac myocytes, which display structural and
functional activity.17–19 However, the use of allogenic embry-
onic stem cells in patients raises substantial concerns. There-
fore, we investigated the potential of adult circulating EPCs
to transdifferentiate into cardiac myocytes.
The results of the present study demonstrate that human
EPCs isolated from the peripheral blood of adults are capable
of transdifferentiating into cardiac myocytes when cocultured
with neonatal rat cardiomyocytes. This transdifferentiation
was evidenced by phenotypic and functional parameters.
Moreover, intercellular gap junctional coupling between rat
cardiomyocytes and human EPCs was demonstrated.
Methods
Patients and Control Subjects
Healthy adult volunteers had neither a history of coronary artery
disease (CAD) nor any clinical signs or symptoms of myocardial
ischemia.
All CAD patients had angiographically documented stenoses of
$50% in any coronary vessel. None of the CAD patients had a
myocardial infarction within 7 days before blood sampling. Patients
with significant comorbidity (infectious diseases, immunosuppres-
sive therapy, cancer, hemodialysis) were excluded. All of the CAD
patients were on standard medical therapy except for an HMG-CoA
reductase inhibitor. A risk factor score (including diabetes mellitus,
smoking, arterial hypertension, hypercholesterolemia, and familial
disposition) was calculated as described previously.9
Informed consent was obtained from all subjects before blood
sampling. The study protocol was approved by the local ethics
committee of the University of Frankfurt.9
Cell Culture Experiments
Neonatal ventricular cardiomyocytes were isolated from 1- to 2-day-
old Sprague-Dawley rats as described previously.20 Noncardiomyo-
cytes (primarily cardiac fibroblasts) were separated from the cardio-
myocytes by differential plating onto plastic dishes. During this step,
2 mg/mL mitomycin C (Sigma) was added. Cardiomyocytes were
plated at a density of 1.23105/cm2 on gelatin-coated wells. Cardiac
fibroblasts (first passage) were plated at a density of 105/cm2 for the
experiments. For immunocytochemistry, cells were plated onto
chamber slides.
EPCs were isolated from the peripheral blood as described
previously.11 After 3 days in culture, adherent EPCs were labeled
with 2.5 mg/mL Dil-acLDL (Cell Systems) for 60 minutes at 37°C
followed by 3 washes with PBS. The nontransferable dye Dil-acLDL
was used to allow live monitoring of the human EPCs during
cocultivation. EPCs were then mixed with freshly isolated cardio-
myocytes at a ratio of 1:4 (10% horse serum, 5% FCS, Invitrogen).
After 2 days, the medium was changed to 5% horse serum and
renewed every 2 days.
Adult human CD341 cells were mobilized to and isolated from the
peripheral blood as described previously.11 CD341 cells were cocul-
tured with rat cardiomyocytes as above.
For some experiments, cardiomyocytes were fixed with 2%
paraformaldehyde in PBS for 15 minutes at room temperature. After
3 washes with PBS, EPCs were added.
Cell Size Measurements and
Immunofluorescence Staining
Cells were stained for cardiac troponin I myocyte enhancer factor 2
(MEF-2) using an antibody that is broadly reactive with MEF-2
family members including MEF-2c (both Santa Cruz), pancadherin,
a-sarcomeric actinin (both Sigma), or atrial natriuretic peptide
(Peninsula Laboratories), followed a biotinylated secondary antibody
and streptavidin-FITC (both Vector Laboratories). Human cells were
identified with a phycoerythrin-conjugated anti-human HLA-DR
antibody (Caltag). Nuclei were stained by DAPI (Sigma).20
Cells were imaged and maximal cell length and surface area were
calculated by use of an Axiovert 100 inverted microscope equipped
with an AxioCam and AxioVision software (all Zeiss).
Detection of Transdifferentiation by
Fluorescence-Activated Cell Sorting
After 6 days in coculture, human EPCs and rat cardiomyocytes were
labeled with a phycoerythrin-conjugated human-specific anti-
HLA-DR antibody (Caltag), permeabilized by use of the Cytofix/
Cytoperm kit (BD Pharmingen), and stained with a FITC-conjugated
(Pierce) anti–a-sarcomeric actinin antibody (clone EA-53, Sigma).
Twenty thousand cells were analyzed on a FACScalibur cell sorter
(BD Biosciences).
Calcium Transient Measurements
Cardiomyocytes and EPCs were cocultured on glass coverslips.
After 6 days, cells were washed with phosphate-free Tyrode’s
solution (in mmol/L: NaCl 132, KCl 4, CaCl2 1.6, MgCl2 1, NaHCO3
12, and glucose 10, at a pH of 7.4, at 37°C and 5% CO2) and
incubated at 37°C (5% CO2) with 5 mmol/L Fluo 4-AM (Molecular
Probes). After 30 minutes, cells were transferred to a heated
microscope chamber superfused with HEPES-modified Tyrode’s
solution (in mmol/L: NaCl 140, KCl 4.7, CaCl2 1.3, MgCl2 1,
HEPES 10, and glucose 5, at a pH of 7.4, at 37°C, in room air). Two
platinum electrodes connected to a Grass stimulator (Grass Instru-
ments) were used for electrical stimulation (1.64 Hz, 5 ms, 5 V).
Images were obtained with a FITC filter set (excitation 488 nm,
emission 512 nm) and a CCD camera (Orca-II, Hamatsu Instru-
ments) connected to an imaging system (Openlab, Improvision).
Calcium transients were averaged by time-matched superimposition
of individual frames.
Dye Transfer Experiments
Cardiomyocytes were labeled with calcein-AM (2.5 mmol/L; Cal-
biochem) for 60 minutes at 37°C. EPCs were labeled separately with
Dil-acLDL and added to the cardiomyocytes at a ratio of 1:4. Cells
were then cocultured for the times indicated. Dye transfer was
measured by flow cytometry in native, unfixed cells by the transfer
of calcein to Dil-acLDL–labeled EPCs.
Single-Cell Microinjection
Sharp microelectrodes were loaded with the fluorescent tracer
Lucifer yellow (4% in 100 mmol/L lithium chloride). Glass cover-
slips containing cocultured EPCs and rat cardiomyocytes were
superfused with modified Tyrode’s solution (in mmol/L: NaCl 132,
KCl 4, CaCl2 1.6, MgCl2 0.98, NaHCO3 20, NaH2PO4 0.36, glucose
10, and Ca21-EDTA 0.05). Cells were impaled using a micromanip-
ulator (5171, Eppendorf). Dye was injected iontophoretically. After
60 seconds, fluorescence was recorded with a fluorescein filter set
(excitation 488, emission 512) and a CCD camera (Zeiss Attoflor
Ratio Vision) to assess dye coupling.
Statistical Analysis
Data are expressed as mean6SEM. An unpaired, 2-tailed t test was
used for the comparison of continuous variables. ANOVA was used
for multiple comparisons. The risk factor score was considered to be
an ordinal variable, and the Spearman rank correlation coefficient
was calculated. For comparison of nominal variables, the Mann-
Whitney test was used.
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Results
Human Blood-Derived EPCs Can
Transdifferentiate Into Cardiomyocytes
We reported previously that human EPCs can be generated
from peripheral blood mononuclear cells.9,11,14 After 3 days,
.95% of the adherent human EPCs expressed several endo-
thelial markers (data not shown; see References 9, 11, and 14).
For the coculture experiments, vital EPCs were separately
labeled by the fluorescent tracer Dil-acLDL before the
coculture. Dil-acLDL is specifically taken up by EPCs but not
by cardiomyocytes (Figure 1A). Once internalized, Dil-
acLDL becomes membrane-bound and cannot be transferred
to adjacent cells in culture. Thus, Dil-acLDL labeling allows
EPC detection in living cells. Importantly, Dil-acLDL is
retained within EPCs for at least 14 days in culture (data not
shown).
The potential of human EPCs to transdifferentiate into
cardiomyocytes was assessed in vitro using a coculture of
human EPCs with rat neonatal cardiomyocytes. Initially,
EPCs from healthy adult volunteers were used.
Within 12 hours of coculture, Dil-acLDL–labeled human
EPCs adhered to cardiomyocytes (Figure 1B). After 6 days of
coculture, many human EPCs had integrated with the rat
cardiomyocytes (Figure 1B). Compared with nonintegrated
EPCs, integrated EPCs displayed significant increases of their
cell length and surface area, similar to adjacent cardiomyo-
cytes (Figure 1C).
After 6 days of coculture, several Dil-acLDL–positive and
human HLA-positive EPCs expressed cardiac-specific pro-
teins such as cardiac troponin I (data not shown) and atrial
natriuretic peptide and myocyte-specific proteins such as
a-sarcomeric actinin and MEF-2 (Figure 2). Furthermore,
sarcomeric organization was observed in some human EPCs
(Figure 2B). In contrast, under basal conditions, EPCs did not
express myogenic marker proteins (Figure 3, A and E, and
data not shown).
Transdifferentiation of EPCs was quantified by flow cy-
tometry analysis (Figure 3). EPCs were identified by a
human-specific HLA-DR antibody (red channel, EPC mark-
er). (Cardio)myocytes were identified by their expression of
Figure 1. Morphology of human EPCs
cocultured with rat cardiomyocytes. A,
Rat cardiomyocytes (left) or human EPCs
(right) were incubated with Dil-acLDL
(red lines) or medium only (blue lines)
followed by flow cytometry analysis. B,
Top: Morphology after 1 day of cocul-
ture. Phase contrast (left) and Dil-acLDL
fluorescence (right) of same field; magni-
fication 3400. Arrows indicate EPCs.
Bottom: Morphology after 6 days of
coculture. Arrowheads indicate transdif-
ferentiated EPCs; arrow indicates an
EPC without altered morphology. C,
Quantification of cell length (left) and sur-
face area (right) of native EPCs, non-
transdifferentiated EPCs, and transdiffer-
entiated EPCs (both after 6 days of
coculture). Shown are mean6SEM of
n512 cells from a representative experi-
ment per group.
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a-sarcomeric actinin, a classic myogenic marker (FITC-
labeled, green channel). Initially, no double-positive cells
were detected (Figure 3A). In contrast, after 6 days of
coculture, 9.9461.39% of the human cells expressed
a-sarcomeric actinin (Figure 3, B and E). Human CD341
hematopoietic progenitor cells also differentiated into actinin-
positive cells with a comparable efficiency (Figure 3, C and D).
Importantly, no transdifferentiation of EPCs was observed
when they were cultured with conditioned medium from rat
cardiomyocytes (Figure 3E).
Calcium Transients in Transdifferentiated EPCs
To obtain proof of cardiomyocyte-like function after trans-
differentiation, we measured calcium transients in living
Dil-acLDL–labeled human EPCs (red fluorescence) using the
calcium indicator fluo-4 (green fluorescence). Transdifferen-
tiated EPCs displayed periodic oscillations in calcium similar
to and synchronized with those in adjacent rat cardiomyo-
cytes (Figure 4). Time-matched averaging of individual
calcium signals revealed that human EPCs and rat cardio-
myocytes generated calcium transients of similar amplitude
and duration (Figure 4D). Only transdifferentiated but not
nondifferentiated human EPCs exhibited calcium transients
similar to rat cardiomyocytes (Figure 4, E and F).
Gap Junctional Communication Between Human
EPCs and Rat Cardiomyocytes
Next, we investigated whether human EPCs can physically
interact with cardiac myocytes. Microinjection of the fluores-
cent dye Lucifer yellow into rat cardiomyocytes revealed
coupling as determined by direct dye transfer to adjacent
EPCs (Figure 5, E and F). Similarly, coupling between
Dil-acLDL–labeled EPCs and rat cardiomyocytes labeled
with the gap junction–permeable fluorescent dye calcein
(green fluorescence) was observed (Figure 5, A through D). A
time-dependent calcein transfer from the cardiomyocytes to
the EPCs resulted in a significant increase in calcein-positive
Dil-acLDL–labeled EPCs (Figure 5B). Because of the colo-
calization of red and green fluorescence, these cells appear
yellow after superimposition of the fluorescent images (Fig-
ure 5B). Quantification by flow cytometry demonstrated that
’60% of the Dil-acLDL–labeled EPCs were positive for
calcein after 24 hours of coculture (Figure 5, C and D).
Interestingly, such dye transfer was not observed when rat
cardiac fibroblasts were labeled with calcein and cocultured
with EPCs (Figure 5D). Addition of the gap junction inhibitor
phorbol 12-myristate 13-acetate (PMA) (50 nmol/L) signifi-
cantly reduced the dye transfer, suggesting that cardiomyo-
cytes are linked to EPCs by gap junctions (Figure 5B).
Similarly, heptanol (1 mmol/L), another gap junction blocker,
partially prevented calcein dye transfer (data not shown).
These data indicate that human EPCs are physically con-
nected to cardiac myocytes by intercellular gap junctions.
Cell-to-Cell Contact but Not Intercellular Fusion
Is Required for Transdifferentiation
Having demonstrated that EPCs and cardiomyocytes are
physically connected, allowing dye transfer between these 2
distinct cell types, we investigated whether gap junctional
exchange of low-molecular-weight molecules is required for
transdifferentiation. Therefore, we incubated the coculture of
EPCs and cardiac myocytes with the gap junction inhibitor
PMA (50 nmol/L) and determined the transdifferentiation of
EPCs into cardiac myocytes by fluorescence-activated cell
sorting analysis. However, the addition of PMA did not
inhibit transdifferentiation of EPCs (124.9618.3% actinin-
positive human cells compared with the control without
PMA; n53; P5NS).
Recent studies reported that phenotypic changes of embry-
onic stem cells may occur as a consequence of cell fusion.21
To investigate whether this mechanism underlies EPC trans-
differentiation, we used paraformaldehyde-fixed cardiomyo-
cytes, which cannot fuse with other cells but have an intact
cell surface for coculture. After 6 days of coculture with fixed
cardiac myocytes, EPCs displayed increases in cell length and
surface area (data not shown). Moreover, after coculture with
fixed cardiac myocytes, several EPCs revealed expression of
Figure 2. Expression of cardiomyocyte proteins and sarcomeric
organization in human EPCs cocultured with rat neonatal car-
diomyocytes. Triple labeling of EPCs after 6 days in coculture
with rat cardiomyocytes. Nuclei (DAPI) are blue (A, C, E), human
EPCs (Dil-acLDL and human HLA) are red, and cardiomyocyte
markers are green; magnification 3400. A and B, a-Sarcomeric
actinin (green); C and D, atrial natriuretic peptide (green); E and
F, myocyte enhancer factor-2 (nuclear expression, green). Cells
without staining of cardiac marker proteins (blue nuclei, C and
D) represent rat fibroblasts.
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cardiac-specific proteins. As shown in Figure 6A, human
EPCs (anti-HLA staining; red fluorescence) showed the
expression of a-sarcomeric actinin (blue fluorescence) and
nuclear MEF-2 staining (green fluorescence).
Cadherins mediate calcium-dependent cell-to-cell contact
and regulate diverse signaling processes.22 To elucidate a
potential role of calcium-dependent cell-to-cell contact, EPCs
were incubated with the calcium chelator EDTA or EGTA.
EDTA and EGTA abolished the adhesion of EPCs to fixed
cardiomyocytes (Figure 6B). Moreover, cadherin staining
was detected at the interface between cardiomyocytes and
EPCs (Figure 6C). Taken together, these data suggest that
calcium-dependent cell-to-cell communication, but not inter-
cellular fusion or gap junctions are essential for EPC
transdifferentiation.
EPCs From CAD Patients Can Also
Transdifferentiate Into Cardiomyocytes
Patients with CAD and risk factors for atherosclerosis have a
significantly reduced number of EPCs compared with healthy
control subjects without cardiovascular risk factors. In addi-
tion, EPCs from CAD patients are functionally impaired, as
evidenced by a significantly reduced migratory activity in cell
culture.9 Because any EPC cell therapy would clinically
target CAD patients, we investigated whether EPCs isolated
from the peripheral blood of CAD patients are also capable of
transdifferentiating into cardiomyocytes.
Therefore, we cocultured EPCs from 14 CAD patients with
rat cardiomyocytes. Morphologically, EPCs from CAD pa-
tients integrated with the rat cardiomyocytes similarly to the
EPCs from healthy volunteers (data not shown). After 6 days
of coculture, the percentage of actinin-positive, transdiffer-
entiated human EPCs was quantified by flow cytometry, and
the results were compared with the data obtained from 15
age- and sex-matched healthy control subjects without any
evidence of CAD. The prevalence of cardiovascular risk
factors tended to be higher among CAD patients, but only the
higher prevalence of hypercholesterolemia reached statistical
significance (Figure 6A).
The survival of human EPCs in the coculture did not differ
between groups (data not shown). As shown in Figure 3,
’10% of EPCs from healthy adult volunteers expressed
Figure 3. Quantification of EPC transdif-
ferentiation into cardiomyocytes. A and
B, Representative flow cytometry analy-
ses of human EPCs after mixing with rat
cardiomyocytes (A) or after 6 days of
coculture with rat cardiomyocytes (B).
Cells were stained with an anti–a-
sarcomeric actinin antibody (green fluo-
rescence) to identify myocytes; human
cells are identified with a human-specific
anti–HLA-DR antibody (red fluorescence).
EPCs are in upper left, rat cardiac fibro-
blasts in lower left, and rat cardiomyo-
cytes in lower right quadrant. Transdiffer-
entiated EPCs expressing a-sarcomeric
actinin are in upper right quadrant in B.
C and D, Representative flow cytometry
analysis of human CD341 cells after mix-
ing with rat cardiomyocytes (C) or after 6
days of coculture with rat cardiomyo-
cytes (D). Cells were stained as above.
E, Quantitative group data. Percentage
of EPCs expressing a-sarcomeric actinin
at baseline (black bar), after 6 days of
coculture with rat cardiomyocytes (white
bar), or after 6 days of culture with
medium conditioned from rat cardiomyo-
cytes (gray bar). Values are mean6SEM.
*P,0.01 vs baseline.
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a-sarcomeric actinin after 6 days of coculture with rat
cardiomyocytes. In contrast, the transdifferentiation effi-
ciency of EPCs from CAD patients was significantly reduced
compared with the control group (Figure 7, A and B).
Interestingly, the EPC transdifferentiation capacity was in-
versely correlated with the number of cardiovascular risk
factors (Figure 7C).
Taken together, EPCs from CAD patients are in principle
capable of transdifferentiating into actinin-positive cells,
albeit less efficiently than EPCs from healthy volunteers.
Discussion
The present study demonstrates that EPCs isolated from the
peripheral blood of healthy adult volunteers and patients with
CAD are capable of transdifferentiating into cardiac myo-
cytes when cocultured with rat cardiomyocytes. After 6 days
of coculture, EPCs displayed typical phenotypic and func-
tional properties of cardiomyocytes. Human EPCs and rat
cardiomyocytes exhibited gap junctional communication, as
evidenced by dye coupling experiments.
In our in vitro system, the transdifferentiation potential of
human adult EPCs was similar to that previously described
for murine embryonic endothelial cells or human semiembry-
onic umbilical endothelial cells.16 Thus, our results extend the
identification of cells capable of transdifferentiation to circu-
lating human adult EPCs. Significantly, human EPCs and
purified CD341 hematopoietic progenitor cells exhibited a
comparable capacity to transdifferentiate into cardiomyo-
cytes, as evidenced by a similar percentage of actinin-positive
cells.
A pivotal functional property of cardiomyocytes is their
excitation-contraction coupling. By use of fluo 4 imaging,
calcium transients of similar amplitude and duration were
detected in transdifferentiated human EPCs and rat cardio-
myocytes. The calcium transients of the transdifferentiated
human EPCs were comparable to the ones described previ-
Figure 4. Calcium transients in transdif-
ferentiated human EPCs. A, Human
EPCs and rat cardiomyocytes (CM) were
labeled with fluo 4 (green fluorescence)
after 6 days of coculture. EPCs are iden-
tified via their Dil-acLDL labeling (red flu-
orescence). B, Phase-contrast image
from same field as in A. Note integrated
and cardiomyocyte-like morphology of
human EPCs. C, Oscillation of calcium
signal (fluorescence in arbitrary units,
A.U.) of human EPC (blue) and rat car-
diomyocyte (purple) from A over time. D,
Time-matched averaging of individual
calcium transients of human EPC (blue)
and rat cardiomyocyte (purple) from A. E
and F, Fluo 4 fluorescence at time 0 ms
(E) and at peak (150 ms, F) of a nondif-
ferentiated (*) and a morphologically
transdifferentiated human EPC (arrow)
together with a rat cardiomyocyte
(arrowhead). Note calcium transient in
transdifferentiated human EPC and rat
cardiomyocyte but not nondifferentiated
human EPC.
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ously for cardiomyocytes generated from human embryonic
stem cells.23 Together, these data demonstrate that human
EPCs are capable of acquiring not only phenotypic (increase
in cell length and area as well as expression and organization
of sarcomeric proteins) but also functional characteristics of
cardiomyocytes.
To be functionally integrated into cardiac tissue, EPCs
must become electrically coupled to neighboring cardiomyo-
cytes. These intercellular connections are typically estab-
lished by gap junctions. Indeed, on coculture, human EPCs
exhibited gap junctional communication with adjacent rat
cardiomyocytes, as evidenced by dye transfer experiments.
Recent studies imply an important role of cell fusion for
phenotypic transdifferentiation.21 In detail, embryonic stem
cells were found to be capable of forming hybrids with
differentiated cells when cocultivated, which leads to epige-
netic reprogramming. Consequently, the altered phenotype of
the embryonic stem cell does not arise from direct conversion
of the cell type but rather from cell fusion. However,
transdifferentiation of EPCs to cardiac myocytes was also
detected when paraformaldehyde-fixed, dead cardiac myo-
cytes were used for coculture. Therefore, the present data
exclude the possibility that cellular fusion is a prerequisite for
the phenotypical change of EPCs to cardiomyocytes (Figure
6). However, our data also demonstrate that cell-to-cell
contact is essential for EPC transdifferentiation, because
conditioned medium containing soluble factors released from
cardiomyocytes was not sufficient to reproduce EPC trans-
differentiation in the absence of cardiomyocytes (Figure 3E).
One possibility is that cadherins may mediate this crucial
cell-to-cell contact. Beyond the physical interaction of coher-
ing cells, cadherins regulate diverse signaling processes, such
as differentiation, proliferation, and migration.22 Indeed, cal-
cium depletion, which prevents cadherin-mediated cell-to-
Figure 5. Gap junctional communication
between EPCs and rat cardiomyocytes.
A through C, Human EPCs were labeled
with nontransferable Dil-acLDL (red fluo-
rescence), and rat cardiomyocytes were
labeled with gap junction–permeable
calcein-AM (green fluorescence) before
coculture. Superimposed images after (A)
4 hours and (B) 16 hours of coculture,
both magnification 3200. Arrows indi-
cate human EPCs that have taken up
calcein. Yellow color results from colo-
calization of red and green fluorescence.
C, Representative flow cytometry analy-
ses after 4 hours (top) or 16 hours (bot-
tom). EPCs that have taken up calcein
dye are in right upper quadrant. D,
Quantitative group data for coculture of
human EPCs with rat cardiomyocytes
without inhibitor (rhombus) or in pres-
ence of gap junction inhibitor PMA (50
nmol/L) (square). As control, human
EPCs were cocultured with rat cardiac
fibroblasts (triangle). Values are
mean6SEM from n53 to 4 independent
experiments per data point. *P,0.05 vs
coculture with inhibitor or coculture with
fibroblasts. E and F, Microinjection. A
single cardiomyocyte with adjacent
human EPCs was microinjected with
Lucifer yellow. E, Phase-contrast image
of injection. F, Fluorescent image 60 sec
after injection. Asterisks indicate cardio-
myocyte; arrows, coupled EPCs.
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cell contact, abolished the adhesion of EPCs to cardiomyo-
cytes. In addition, cadherins are expressed in EPCs and are
localized to the sites of cell-to-cell contact between EPCs and
cardiomyocytes. These data support a potential role of cad-
herins for EPC transdifferentiation. However, further exper-
iments are necessary to prove that concept and to identify the
role of specific cadherins.
In vivo experiments in animals demonstrated that injection
of EPCs improves cardiac neovascularization and function.5
Therefore, EPCs might be useful for cell therapy to poten-
tially promote both neovascularization and cardiac regenera-
tion in patients with ischemic heart disease. Importantly,
EPCs isolated from the peripheral blood of CAD patients
were also capable of transdifferentiating into cardiomyocyte-
like cells in our cell culture model, albeit with a lower
efficiency than EPCs from healthy adult volunteers. These
data are consistent with our previous observation that EPCs
from CAD patients are functionally impaired in cell culture.9
In summary, adult blood-derived human EPCs from
healthy adult volunteers and CAD patients can transdifferen-
tiate into cardiomyocytes in vitro after coculture with neona-
tal rat cardiac myocytes. Ultimately, these cells might be
useful for a potential cell therapy to promote cardiac regen-
eration in patients with ischemic heart disease.
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Figure 6. EPCs can transdifferentiate
when cocultivated with fixed cardiomyo-
cytes. A, Transdifferentiation of EPCs on
paraformaldehyde-fixed cardiomyocytes.
After 6 days, immunostaining against
human HLA (red fluorescence),
a-sarcomeric actinin (blue fluorescence),
and MEF-2 (green fluorescence) was
performed (n53). Lower right, Black-and-
white image for optimized visualization of
striated myofilaments. Arrow points to a
human cell expressing MEF-2 and
a-sarcomeric actinin. B, Adhesion of
EPCs to paraformaldehyde-fixed cardio-
myocytes is calcium-dependent.
Di-acLDL–labeled EPCs were incubated
with fixed cardiomyocytes in presence or
absence of EDTA and EGTA for 12
hours. Then, adherent EPCs were
counted. Values 6SEM (n54) are
expressed as percentage of control. C,
Cadherin expression at interface
between EPCs and cardiomyocytes.
After 6 days of coculture, cells were
stained for cadherins (green fluores-
cence); nuclei are blue and human cells
are red.
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Figure 7. EPCs from CAD patients can transdifferentiate into
actinin-positive cells. A, Clinical characteristics of control group
(No CAD) and CAD patients. For metric parameters, mean6SEM
is shown. B, Individual transdifferentiation data points for control
group (No CAD) and CAD patients. C, EPC transdifferentiation
capacity was correlated with total number of risk factors for
CAD. Pooled data from control and CAD group. For 3 individu-
als in A, a risk factor score could not be calculated.
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